News | October 23, 2014

One-year Outcomes Good for Superficial Femoral Artery Stent

October 23, 2014 — The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease. Randomized trials have shown favorable results for self-expanding nitinol stents compared with balloon angioplasty. A new report seeks to test this treatment in a real-world population of patients enrolled in an observational registry.

The Journal of Endovascular Therapy offers a prospective multicenter observational study of patients with symptomatic superficial femoral artery stenosis. A total of 998 patients suffering from chronic limb ischemia were enrolled at 13 German medical centers. Twelve-month outcomes of the participants were assessed.

The median lesion length was 8 cm, but there was no restriction on the length of lesion to be treated. The authors cite this criterion as supporting the real-world aspect of the study population. Rather than including primarily high-risk patients, a general mix of patients participated in the study. However, a third of the patients had diabetes, and 43 percent were current smokers.

In all, 1,050 lesions were treated. Twelve months after surgery, target lesion revascularization — the primary endpoint of the study — was achieved in 136, or 17 percent, of the patients. Restenosis occurred in 24 percent of the patients and reocclusion in 10 percent. These results indicate that stent use is safe and is delivering favorable outcomes at the one-year mark.

A commentary in the same issue asserts that the “real-world” study group is actually representative of a narrower set of patients, largely because the median lesion length was less than 10 cm—a length that has previously shown good success with intervention. The author notes that, although the study validates that superficial femoral artery stenting is producing satisfactory patency results, patient quality of life and functionality measures might better represent success.

For more information: www.jeytonline.org

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init